Both set their sights on 2025 Cancer TSUNAMI
Jan. 8, 2024 (CNBC) – J&J to acquire cancer drug developer Ambrx Biopharma for $2 billion
Johnson & Johnson said it will acquire Ambrx Biopharma for $2 billion, picking up a drugmaker specializing in one of the hottest areas of cancer treatment.
The deal makes J&J the latest drugmaker to bet on antibody-drug conjugates, or ADCs (same tech as Pfizer’s latest $43 billion Seagen acquisition)
The acquisition also comes as J&J scrambles to fill a revenue hole that’s approaching in 2025 (!)
Johnson & Johnson on Monday said it will pay $2 billion in cash to acquire Ambrx Biopharma
“Ambrx’s pipeline and ADC platform present exciting future opportunities to deliver enhanced, precision biologics as we look to transform the treatment of cancer and improve patients’ lives”
Under the terms of the deal, J&J will pay $28 a share for Ambrx, or about DOUBLE the firm’s Friday closing price of $13.63. J&J expects to close the deal in the first half of 2024.
Jan. 8, 2024 (CNBC) – J&J to acquire cancer drug developer Ambrx Biopharma for $2 billion

Johnson & Johnson said it will acquire Ambrx Biopharma for $2 billion, picking up a drugmaker specializing in one of the hottest areas of cancer treatment.
The deal makes J&J the latest drugmaker to bet on antibody-drug conjugates, or ADCs (same tech as Pfizer’s latest $43 billion Seagen acquisition)
The acquisition also comes as J&J scrambles to fill a revenue hole that’s approaching in 2025 (!)
Johnson & Johnson on Monday said it will pay $2 billion in cash to acquire Ambrx Biopharma
“Ambrx’s pipeline and ADC platform present exciting future opportunities to deliver enhanced, precision biologics as we look to transform the treatment of cancer and improve patients’ lives”
Under the terms of the deal, J&J will pay $28 a share for Ambrx, or about DOUBLE the firm’s Friday closing price of $13.63. J&J expects to close the deal in the first half of 2024.